Please login to the form below

Not currently logged in

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

The acquisition includes TeneoTwo’s phase 1 clinical-stage T-cell engager


In a new deal valued at up to $1.27bn, AstraZeneca (AZ) has acquired biotechnology firm TeneoTwo.

The agreement includes the acquisition of TeneoTwo’s phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, which is currently being assessed in the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma.

By taking on TNB-486, AZ will reinforce its haematological cancer pipeline. To that end, the company aims to accelerate R&D surrounding this potential new medicine for B-cell haematologic malignancies, such as diffuse large B-cell lymphoma and follicular lymphoma.

Following AZ’s success with Calquence (acalabrutinib) – a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor – TNB-486 will further diversify the company’s haematology pipeline that have the potential capacity to address broad spectrum of blood cancers.

TNB-486 is in a class of therapeutic antibodies referred to as T-cell engagers, which show promise as a therapeutic approach in tackling haematologic malignancies and solid tumours. T-cell engagers are bispecific molecules that are developed to redirect the immune system’s T-cells to identify and destroy cancer cells.

It has been agreed between the companies that AZ will acquire all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m on completion of the deal.

According to the terms of the deal, AZ will make additional contingent R&D-related milestone payments of up to $805m, followed by additional contingent commercial-related milestone payments of up to $360m to TeneoTwo’s equity holders.

The deal is expected to be finalised in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Anas Younes, senior vice president haematology R&D, AZ said: “By redirecting the body’s natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes.

“We believe this innovative molecule, which was designed to optimise the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting.”

Article by
Fleur Jeffries

5th July 2022

From: Sales, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments....
Keith Berelowitz
Transforming clinical trials to accelerate drug development
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...